ACADIA Pharmaceuticals Inc (ACAD)

33.69
1.50 4.40
NASDAQ : Health Care
Prev Close 35.23
Open 34.95
Day Low/High 33.25 / 35.00
52 Wk Low/High 16.64 / 50.40
Volume 3.62M
Avg Volume 1.86M
Exchange NASDAQ
Shares Outstanding 114.01M
Market Cap 3.91B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These 5 Biotech Stocks Are Ready for a Volatility Break

These 5 Biotech Stocks Are Ready for a Volatility Break

The squeeze is on these stocks, and they are poised for volatile moves.

Don't Be Fooled, There's Still Complacency Here

We should rebound and then come back down again.

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These stocks are within range of triggering big breakout trades.

ACADIA Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference On September 12, 2016

ACADIA Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference On September 12, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Todd S. Young, Executive Vice President, Chief Financial Officer Of ACADIA Pharmaceuticals (Photo: Business Wire)

Todd S. Young, Executive Vice President, Chief Financial Officer Of ACADIA Pharmaceuticals (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

ACADIA Pharmaceuticals Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

Tracking Bullish and Bearish Reversals

These stocks have made U-turns in the past week.

Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta

Biotech Stock Mailbag: Heron, Acadia, Exact Sciences, Sarepta

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

ACADIA Pharmaceuticals Prices Public Offering Of Common Stock

ACADIA Pharmaceuticals Prices Public Offering Of Common Stock

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today...

Highlighted Post-Market Laggard: ACADIA Pharmaceuticals (ACAD)

Highlighted Post-Market Laggard: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a post-market laggard candidate

ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results

ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

Biotech Pop-Up Party in Full Swing

Biotech Pop-Up Party in Full Swing

The beaten-down biotech sector is making an impressive comeback. The sector seems to be rebounding after tumbling by more than 40%.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

ACADIA Pharmaceuticals To Announce Second Quarter 2016 Financial Results On August 4, 2016

ACADIA Pharmaceuticals To Announce Second Quarter 2016 Financial Results On August 4, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Biogen Should Either a Buyer or a Seller Be

Biogen Should Either a Buyer or a Seller Be

The company sans CEO Scangos needs to do some type of deal in the coming months.

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Here Are Some Small-Cap Pharma M&A Targets After Relypsa Deal

Investors may want to look at some small-cap pharma names that could be takeover targets like Relypsa.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Strong On High Relative Volume: ACADIA Pharmaceuticals (ACAD)

Strong On High Relative Volume: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a strong on high relative volume candidate

ACADIA Pharmaceuticals Added To Large-Cap Russell 1000 Market Index

ACADIA Pharmaceuticals Added To Large-Cap Russell 1000 Market Index

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Analysts' Actions -- Domino's, McDonald's, Priceline, Tesla and More

Analysts' Actions -- Domino's, McDonald's, Priceline, Tesla and More

Here are Wednesday's top research calls, including downgrades for Domino's Pizza, McDonald's and Tesla, and an upgrade for Priceline.

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 21, 2016

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 21, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a post-market leader candidate

4 Possible Acquisition Targets in Biotech

These mid-caps would do well by themselves, but could tempt bigger companies.

ACADIA Pharmaceuticals To Present At The Goldman Sachs 37th Annual Global Healthcare Conference On June 8, 2016

ACADIA Pharmaceuticals To Present At The Goldman Sachs 37th Annual Global Healthcare Conference On June 8, 2016

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available For The Treatment Of Hallucinations And Delusions Associated With Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available For The Treatment Of Hallucinations And Delusions Associated With Parkinson's Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway

Cramer says he's no longer negative on Advanced Micro Devices and thinks Micron Technology is OK.

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

Jim Cramer's 'Mad Money' Recap: Own This Rally and Buy These Stocks

When you get an unexpected rally, just go with it, Cramer says.